You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

 

Online download statistics by month:

Online download statistics by month: December 2020 to January 2026

AbstractFullPdf
Dec 202016416446
Jan 2021273273136
Feb 202117217448
Mar 202120020147
Apr 202115315338
May 202115915935
Jun 202116916936
Jul 202113013023
Aug 202113113145
Sep 2021929247
Oct 202114214294
Nov 202110910749
Dec 2021989952
Jan 202212613851
Feb 2022878737
Mar 2022727272
Apr 2022788041
May 202211211249
Jun 2022858752
Jul 2022616248
Aug 2022595947
Sep 2022667369
Oct 2022555952
Nov 2022777747
Dec 2022494924
Jan 2023545428
Feb 2023787829
Mar 2023373842
Apr 2023434431
May 2023575727
Jun 2023485030
Jul 2023454625
Aug 2023343616
Sep 2023464625
Oct 2023444424
Nov 2023404024
Dec 2023555537
Jan 2024636445
Feb 2024555627
Mar 2024676884
Apr 2024525240
May 2024727145
Jun 202411111438
Jul 2024454626
Aug 2024696874
Sep 2024434333
Oct 2024525329
Nov 2024656626
Dec 2024838548
Jan 2025797948
Feb 2025565648
Mar 2025777756
Apr 2025808150
May 2025566047
Jun 2025262722
Jan 2026110
Total465247042409